Brett Marck
Overview
Explore the profile of Brett Marck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graham L, True L, Gulati R, Schade G, Wright J, Grivas P, et al.
Prostate
. 2021 Mar;
81(7):418-426.
PMID: 33755225
Background: Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to evaluate...
2.
Kaipainen A, Zhang A, Gil da Costa R, Lucas J, Marck B, Matsumoto A, et al.
Prostate
. 2019 Aug;
79(13):1530-1542.
PMID: 31376206
Background: Testosterone is a driver of prostate cancer (PC) growth via ligand-mediated activation of the androgen receptor (AR). Tumors that have escaped systemic androgen deprivation, castration-resistant prostate cancers (CRPC), have...
3.
Mostaghel E, Nelson P, Lange P, Lin D, Taplin M, Balk S, et al.
J Clin Oncol
. 2013 Dec;
32(3):229-37.
PMID: 24323034
Purpose: Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely ablate tissue androgens may limit suppression of PCa growth....
4.
Tamae D, Byrns M, Marck B, Mostaghel E, Nelson P, Lange P, et al.
J Steroid Biochem Mol Biol
. 2013 Jul;
138:281-9.
PMID: 23851165
Prostate cancer is the most frequently diagnosed form of cancer in males in the United States. The disease is androgen driven and the use of orchiectomy or chemical castration, known...
5.
Cai C, Chen S, Ng P, Bubley G, Nelson P, Mostaghel E, et al.
Cancer Res
. 2011 Aug;
71(20):6503-13.
PMID: 21868758
Relapse of castration-resistant prostate cancer (CRPC) that occurs after androgen deprivation therapy of primary prostate cancer can be mediated by reactivation of the androgen receptor (AR). One important mechanism mediating...